Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Novartis to Invest USD 500 Million in New Singapore Facility

By BiotechDaily International staff writers
Posted on 19 Nov 2012
Novartis (Basel, Switzerland) will pay more than USD 500 million to construct a new biotech production site in Singapore to support its growing pipeline of biologics.

First announced in 2007 as a USD 700 million investment, the facility was put on hold after Novartis formed a biologics production partnership with Lonza (Basel, Switzerland), a global biopharmaceuticals supplier, in 2008. The project has now been revived, and construction of the new site is planned for early 2013, and is expected to be operational by the end of 2016. The reasons behind the delay and the decision to reduce the investment by USD 200 million were stated as a desire to better align capacity needs and scope requirements with the future pipeline.

The new facility will focus on drug substance manufacturing based on cell culture technology, such as monoclonal antibodies treatments for cancers and autoimmune and respiratory diseases. The new facility will be based at the same location as Novartis’ existing pharmaceutical production facility in Tuas (Singapore), and will be designed to operate in a flexible manner to handle both small and large-scale volumes and to support clinical and commercial production of potential new products.

“We have chosen Singapore as strategic supply point as it offers a wide range of advantages due to its strong local biomedical presence and knowledge, skilled labor, as well as proximity to growth markets in Asia,” said Joseph Jimenez, CEO of Novartis. “This investment further strengthens our strategy to establish key strategic sites based on technological competencies. Singapore will be strengthened through a new state-of-the-art facility for biotechnology which is a growing segment of our business.”

Novartis already has several operations in Singapore, including its tropical diseases institute, the Asia-Pacific head offices, and two production facilities for its eye-care unit Alcon.

Related Links:

Novartis
Lonza




Channels

Genomics/Proteomics

view channel
Image: In mice, mitochondria (green) in healthy (left) and Mfn1-deficient heart muscle cells (center) are organized in a linear arrangement, but the organelles are enlarged and disorganized in Mfn2-deficient cells (right) (Photo courtesy of the Rockefeller Press).

Cell Biologists Find That Certain Mitochondrial Diseases Stem from Coenzyme Q10 Depletion

A team of German cell biologists has linked the development of certain mitochondrial-linked diseases to depletion of the organelles' pool of coenzyme Q10 brought about by mutation in the MFN2 gene, which... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.